Apple Inc. (AAPL): 2 Possible Solutions for the Company

Page 1 of 2

Apple Inc. (NASDAQ:AAPL) is continuing to lick the wounds to its stock, which is on its way to dropping about 12 percent Thursday in the wake of its weak forecast guidance Wednesday evening. While there is much chagrin on the future of the company, as it forecasted lower profit margins and lower revenue growth in the current quarter. What is a company to do to fight off any further freefall in its stock? Well, there is one tech reporter who is taking a stab at a couple of product and service ideas that he believes would improve Apple’s innovation.

A recent post suggests an upgrade to one existing product, and a way for Apple Inc. (NASDAQ:AAPL) to use some of its tremendous war chest of cash – and no, it’s not raising dividends or executing a more intense stock buyback.

Jony Ive, Apple Inc. (NASDAQ:AAPL)

Photo courtesy of  Dmitry Baranovskiy via Flickr

The first idea involves the MacBook Air device. This post gives some rationale for turning that laptop into a convertible device – suggesting that Apple Inc. (NASDAQ:AAPL) could set up PC sales while also catering to the tablet market by making the screen of the MacBook Air detachable from the keyboard and touch-capable. That would make it a great fit to run Windows 8 by Microsoft Corporation (NASDAQ:MSFT)! OK, just kidding.

The other idea seems like more of a stretch, but also possible. There has been much made about Apple Inc. (NASDAQ:AAPL) continuing to develop its own ecosystem, and perhaps the next natural step to that siloed ecosystem could be in developing its own wireless or cellular network for its iPhones and iPads. In this article, it is postulated that Apple could cut down on some overhead by buying a cell carrier – in this case, US Cellular – that could be an exclusive provider of iDevices. What might this mean for Apple, and for Apple users?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!